Anti-Human HLA DR beta Recombinant Antibody (Apolizumab) (CAT#: TAB-150)

Recombinant monoclonal antibody to HLA DR beta.

Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Formats:
  • Isotype Switching:
  • Fc Engineering:
  • Modalities:
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
Normal Tissue
RNA Expression

Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Mouse
  • Derivation
  • Humanized (from mouse)
  • Type
  • IgG1
  • Specificity
  • Tested positive against native human antigen.
  • Species Reactivity
  • Human
  • Applications
  • Suitable for use in ELISA, IP, FC, FuncS, Neut, IF, ICC and most other immunological methods.
  • CAS
  • 267227-08-7
  • Generic Name
  • Apolizumab
  • UNII
  • G88KCP51RE
  • Related Disease
  • Chronic lymphocytic leukemia (CLL) (refractory)

Product Property

  • Purity
  • >97%, by SDS-PAGE under reducing conditions and visualized by silver stain.
  • Storage
  • Store at -20°C for long-term storage. Store at 2-8°C for up to one month. Avoid freeze/thaw cycles.

Target

  • Alternative Names
  • Apolizumab;267227-08-7;1D10;HU1D10;K8-355;HLA-DRB1;major histocompatibility complex, class II, DR beta 1;HLA DR1B;DW2.2/DR2.2;MHC class II antigen;lymphocyte antigen DRB1;MHC class II HLA-DRw10-beta;human leucocyte antigen DRB1;MHC class II HLA-DR beta 1

Related Resources

  • Biosimilar Overview
Please refer to Apolizumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Apolizumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Apolizumab"

Afuco™ Anti-HLA-DRB1 ADCC Recombinant Antibody, ADCC Enhanced (AFC-TAB-150)
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to HLA DR beta.
DrugMonitor™ Anti-Apolizumab Antibody (VS-1224-YC107)
Apolizumab is a humanized monoclonal antibody studied as a treatment for hematologic cancers. The DrugMonitor™ Anti-Apolizumab Antibody (VS-1224-YC107) is an anti-drug antibody (ADA) against Apolizumab. This drug-based antibody is raised in mice immunized with the Apolizumab. The anti-Apolizumab antibody may be used in ELISA, pharmacokinetics (PK), and pharmacodynamics (PD) analyses, or serves as a reference standard in ADA assays. It also is an excellent tool for therapeutic drug monitoring, allowing to evaluate the drug efficacy and determine the drug concentration of the Apolizumab in samples.

See other products for "HLA-DRB1"

Select a product category from the dropdown menu below to view related products.
Please select product type
Fab Antibody Products ScFv Antibody Products Rabbit Monoclonal Antibody Products MHC Tetramer Products for Cancer IgG Antibody Products ADCC Enhanced Antibody Products Non-Human Primate (NHP) Antibody Products

Customer Reviews and Q&As

Submit a review or a question

There are currently no Customer reviews or questions for TAB-150. Click the button above to contact us or submit your feedback about this product.

Popular products with customers


For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

  • 0
  • 0
Cart
    Go to compare

    Go to compare